Video Insights

Targeting VEGF Pathways in Advanced NETs: Ramucirumab Plus Somatostatin Analog Therapy
Dr. Perez breaks down her study that investigated the use of ramucirumab and somatostatin in patients with advanced NETs.
Advertisement
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti highlights 100% response with PD-1 blockade in dMMR rectal cancer and new chemoimmunotherapy for anal cancer.
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti shares BREAKWATER, CheckMate 8HW, and CHALLENGE results improving metastatic colorectal cancer outcomes.
Sakti Chakrabarti, MDColorectal Cancer | July 17, 2025
Dr. Chakrabarti highlights ATOMIC as the new standard for stage III dMMR colon cancer and compares it to the NICHE approach.
Christopher Lieu, MDEsophageal Cancer | July 16, 2025
Dr. Lieu lists and describes DESTINY-Gastric04, CHALLENGE, MATTERHORN, BREAKWATER, and ATOMIC.
Laura W. Goff, MDLiver Cancer | July 10, 2025
Dr. Goff shares how she chooses between atezo/bev and doublet IO regimens like durva/trem or ipi/nivo for patients with aHCC.
Scott Kopetz, MD, PhDColorectal Cancer | July 10, 2025
Dr. Kopetz explains how BREAKWATER aligns with Project FrontRunner to support accelerated approval in BRAF V600E-mutated CRC.
Erica Barnell, MD, PhDColorectal Cancer | June 18, 2025
Dr. Barnell discusses ColoSense's NCCN Guidelines inclusion for CRC and how it impacts the cancer screening landscape.
Aiwu (Ruth) He, PhDLiver Cancer | June 17, 2025
Dr. He shares her insights on the evolving role of single-agent vs combination IO in the neoadjuvant setting for aHCC.
Yelena Janjigian, MDGastric Cancer | June 16, 2025
Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Filippo Pietrantonio, MDGastric Cancer | June 10, 2025
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
Benjamin Weinberg, MD, FACPColorectal Cancer | June 10, 2025
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Vincent Picozzi, MDPancreatic Cancer | June 10, 2025
Dr. Picozzi details PANOVA-3, where TTFields with chemo showed significant survival gains in advanced pancreatic cancer.
Jeanne Tie, MD, MBChBASCO 2025 | June 6, 2025
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Zev Wainberg, MD, MScGastric Cancer | June 6, 2025
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Christopher Lieu, MDColorectal Cancer | June 5, 2025
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
Ronan Kelly, MDEsophageal Cancer | June 3, 2025
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Richard Kim, MDBile Duct Cancer | June 3, 2025
Dr. Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ BTC.
Richard S. Finn, MDLiver Cancer | June 3, 2025
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Advertisement